A new UBC research study led by Dr. Laura Schummers found a 49 per cent jump in the number of "long-acting reversible ...

If Biodexa's eRapa treatment is shown to be successful in its Phase 3 study and the treatment gets approved, the company believes it would have first-mover advantage in what it estimates is a $7 ...

As Alberta endures its worst year for measles since the 1970s, public health nurses from around the world are gathered in ...

We love using the city as our stage, but I like that we always begin with the artist—often, the actual space is the final ...